SCHEMBL19852330

SCHEMBL19852330

Fc1ccc(OC2CCN(CCC3COc4ccccc43)CC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 4/20 0.45
HTR2A P28223 1/20 0.45
KCNH2 Q12809 2/20 0.42
CARM1 Q86X55 1/20 0.42
PRMT6 Q96LA8 1/20 0.42
ADRA1B P35368 1/20 0.40
ADRB2 P07550 1/20 0.39
HRH3 Q9Y5N1 2/20 0.38
SSTR5 P35346 1/20 0.38
FPR2 P25090 1/20 0.37
PROKR1 Q8TCW9 1/20 0.37
FFAR1 O14842 1/20 0.36
PLA2G1B P04054 1/20 0.36
ATG4B Q9Y4P1 1/20 0.36
GAA P10253 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19852325 0.90 KCNH2 (0.53) HTR7HTR2AKCNH2CARM1PRMT6
SCHEMBL21072473 0.89 HTR7 (0.42) HTR7HTR2ACARM1PRMT6ADRB2
SCHEMBL19852425 0.85 HTR7 (0.42) HTR7HTR2AKCNH2CARM1PRMT6
SCHEMBL19852328 0.83 HTR7 (0.41) HTR7HTR2ACARM1PRMT6ADRA1B
SCHEMBL19852322 0.83 HTR7 (0.48) HTR7HTR2ACARM1PRMT6ADRA1B
SCHEMBL19838628 0.81 HTR2A (0.41) HTR7HTR2AKCNH2CARM1PRMT6
Hydrochloric Acid SCHEMBL19838581 0.80 HTR2A (0.41) HTR7HTR2AKCNH2CARM1PRMT6
SCHEMBL19838875 0.80 HTR7 (0.54) HTR7HTR2ACARM1PRMT6ADRA1B
Hydrochloric Acid SCHEMBL19838877 0.79 HTR7 (0.53) HTR7HTR2ACARM1PRMT6ADRA1B
SCHEMBL19852525 0.78 KCNH2 (0.46) HTR7HTR2AKCNH2ADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SUNOVION PHARMACEUTICALS INC. (US) 2021-11-30 US disclosed
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SUNOVION PHARMACEUTICALS INC. (US) 2021-11-30 US disclosed
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2019-06-27 US disclosed
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2019-06-27 US disclosed
WO-2018026371-A1 DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2018-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SCN2A, HTR2A, HTR2C HTR7 112/4885HTR2A 2/4885KCNH2 158/4885
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SCN2A, HTR2A, HTR2C HTR7 112/4885HTR2A 2/4885KCNH2 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.